In uveal melanoma (UM) cells, HDAC2 inhibitors restore PD-L1 acetylation, prevent its nuclear entry, and inhibit p-STAT3 binding to the EGR1 promoter region, reducing EGR1 expression and suppressing angiogenic capacity. Here, EGR1 is linked to uveal melanoma.